Skip to Content
Merck
CN
HomeCancer ResearchAuthenticated Liver Cancer Cell Lines for Cancer Research

Authenticated Liver Cancer Cell Lines for Cancer Research

Amongst liver cancers, the incidence of hepatocellular carcinoma (HCC) is increasing and has a high mortality rate. Chronic hepatitis B- or hepatitis C-induced cirrhosis is the leading risk factor for HCC. For reasons that are not entirely known, males may be three to five times more likely than females to develop HCC, the most common type of liver cancer. 83% of cases are diagnosed in less-developed countries, with the highest rates found in east and southeast Asia and in middle and western Africa; rates are lower in south-central and western Asia. The five-year survival rate is 31% for patients who are diagnosed at an early stage, but drops to 3% if cancer has metastasized to other tissues of the body.1

Types of Liver Cancer

Hepatocellular carcinoma accounts for 80% of all adult liver cancers. Cholangiocarcinoma (bile duct cancer) and angiosarcoma comprise 10-20% and 1% of liver cancer diagnoses, respectively.

Risk Factors

The major risk factor for liver cancer is exposure to hepatitis viruses and environmental pathogens. Hepatitis B virus (HBV) infection accounts for 60% of total liver cancer, and hepatitis C virus (HCV) is responsible for 33%. Other risk factors include alcohol-related cirrhosis, nonalcoholic fatty liver disease, and obesity.

Mutations

The most commonly mutated genes in liver cancer are TP53CTNNB1TERTHNF1ALRP1BARID1AAXIN1ARID2KMT2C, and IL6ST.

Click on the genes (above) to find relevant products (antibodies, shRNA, siRNA, primers, CRISPR plasmids) for your research study.

Small Molecules/Monoclonal Antibodies

Small molecule compounds and antibodies can be used to target cancer cells and block tumor growth and progression.  The most common strategy for hepatocellular carcinoma is inhibition of angiogenesis signals.  Drugs used to target liver cancer include:

  • Sorafenib Tosylate (Nexavar)
  • Regorafenib (Stivarga)

Applications

Cancer cell lines are essential for cancer research, and provide an accessible, cost-effective model for cellular behavior and response. Based on cell phenotype and experimental need, cell lines have the potential for utility in multiple applications. Some examples of application-specific cell line use are included below.

References

2.
Liu C, Chen K, Chen P. 2015. Treatment of Liver Cancer. Cold Spring Harb Perspect Med. 5(9):a021535. https://doi.org/10.1101/cshperspect.a021535
3.
Tundis R, Loizzo MR, Menichini F, Bonesi M, Colica C, Menichini F. 2011. In vitro Cytotoxic Activity of Extracts and Isolated Constituents of Salvia leriifoliaBenth. against a Panel of Human Cancer Cell Lines. Chemistry & Biodiversity. 8(6):1152-1162. https://doi.org/10.1002/cbdv.201000311
4.
Bonesi M, Tundis R, Deguin B, Loizzo MR, Menichini F, Tillequin F, Menichini F. 2008. In vitro biological evaluation of novel 7-O-dialkylaminoalkyl cytotoxic pectolinarigenin derivatives against a panel of human cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 18(20):5431-5434. https://doi.org/10.1016/j.bmcl.2008.09.037
5.
ZHANG Q, CAO L, CHENG S, ZHANG A, JIN X, LI Y. 2015. p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB. 33(3):1335-1341. https://doi.org/10.3892/or.2015.3715
6.
Ramaiahgari SC, den Braver MW, Herpers B, Terpstra V, Commandeur JNM, van de Water B, Price LS. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch Toxicol. https://doi.org/10.1007/s00204-014-1215-9
7.
Chen H, Yang C, Chen J, Yueh T, Hu M. 2015. Multicarotenoids at Physiological Levels Inhibit Metastasis in Human Hepatocarcinoma SK-Hep-1 Cells. Nutrition and Cancer. 67(4):676-686. https://doi.org/10.1080/01635581.2015.1019633
8.
Liu YM, Xia Y, Dai W, Han HY, Dong YX, Cai J, Zeng X, Luo FY, Yang T, Li YZ, et al. 2014. Cholesterol-conjugated let-7amimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy. BMC Cancer. 14(1): https://doi.org/10.1186/1471-2407-14-889
9.
Sells MA, Chen ML, Acs G. 1987. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.. Proceedings of the National Academy of Sciences. 84(4):1005-1009. https://doi.org/10.1073/pnas.84.4.1005
10.
Hu Q, Wood CR, Cimen S, Venkatachalam AB, Alwayn IPJ. Mitochondrial Damage-Associated Molecular Patterns (MTDs) Are Released during Hepatic Ischemia Reperfusion and Induce Inflammatory Responses. PLoS ONE. 10(10):e0140105. https://doi.org/10.1371/journal.pone.0140105
11.
Dou L, Meng X, Sui X, Wang S, Shen T, Huang X, Guo J, Fang W, Man Y, Xi J, et al. 2015. MiR-19a regulates PTEN expression to mediate glycogen synthesis in hepatocytes. Sci Rep. 5(1): https://doi.org/10.1038/srep11602
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?